$MRK Hits a Fresh High After Landmark Cancer Vaccine Trial Success
@Trend_Radar:
$Merck(MRK)$ $Merck & Co., Inc.(MRK) Surged +3.84% to $156.45: mRNA Cancer Vaccine Breakthrough Pushes Pharma Giant to All-Time High, $160 Breakout Zone in Sight Latest Close Data MRK closed at $156.45 on August 26, 2026, up +3.84% (+$5.79), finishing just $0.47 below the fresh 52-week high of $156.92 set intraday. The stock has now rallied over 100% from its 52-week low of $77.58. Core Market Drivers The rally is fueled by the landmark Phase III INTerpath-001 trial success for Merck's personalized mRNA cancer vaccine (intismeran autogene) combined with Keytruda, hitting both primary and key secondary endpoints — a global first. Multiple firms, including Morgan Stanley (upgraded to Overweight, PT raised from $116 to $179), have lifted ratings a